Digital pathology is defined as an image-based information setting enabled by computer technology that allows the management of information generated through a digital slide. Digitalization of pathology has led to the automation of tests during diagnosis. For example, a single digital instrument can perform tests that were previously carried out using five instruments by pathologists. Digital pathology solutions offer a scrutiny & analysis of images on a computer, high-resolution sample scanning, and online storage of digital slides, which enable pathologists to cross examine slides without physical evidences.
The German digital pathology market is projected to garner revenue worth $58 million by 2022, registering a CAGR of 12.1% over the forecast period. The growth of the market is attributed to factors such as efficient cost of digital pathology products, ease of virtual transportation of slides, high efficiency of digital pathology systems, and more efficiency. In addition, higher adoption of digital pathology over conventional pathology treatments further drives the world market. On the other hand, barriers such as lack of reimbursement, lack of skilled personnel, and unwillingness of older pathologists to adopt to new technology are some of the major factors expected to restrain the market growth. However, rise in initiatives towards commercialization of cost-efficient digital pathology systems would offer profitable growth opportunities for service providers in the future.
The German digital pathology market is segmented on the basis of product and end users. Based on product, the market is classified into Whole Slide Imaging (WSI), image analysis informatics, information management system storage & communication, and telepathology. Whole slide imaging is the highest revenue-generating segment as it is the most preferred method and is used to produce digital slides by scanning the whole glass slide. Similarly, by end user, the market is segmented into educational institutes, hospitals & diagnostic centers, and pharma & biotechnology companies.
Companies have adopted product launch and collaboration as their key development strategies. Increase in focus on product launch is mainly for the development of innovative technologies in the field of digital pathology. In March 2016, Definiens launched "Immunoprofiling Panel" to screen their target biomarkers and measure immune response, thereby expanding its product portfolio.
KEY BENEFITS FOR STAKEHOLDERS:
In-depth analysis is carried out based on market estimations of the key segments from 2014 to 2022.
The report provides comprehensive analysis of factors that drive and restrict the growth of the German digital pathology market.
Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
The report also provides quantitative as well as qualitative market trends to assist the stakeholders understand the situations prevailing in the market.
Competitive analysis of key players is conducted to help stakeholders to understand the inherent trends followed by their competitors and make the necessary amendments to the existing expansion plans
KEY MARKET SEGMENTS:
By Product
Whole Slide Imaging
Image Analysis Informatics
Information Management System Storage & Communication
Telepathology
By End User
Educational Institutes
Hospitals and Diagnostic Centers
Pharmaceutical & Biotechnology Companies
Key players operating in the market include:
Visiopharm
Digipath Inc.
Koninklinje Philips N. V.
PerkinElmer, Inc.
Danaher Corporation (Leica Microsystem)
Nikon Corporation
Carl Zeiss AG
Definiens AG
VMscope GmbH
microDimensions GmbH
Other players in the value chain include:
Indica Labs
Hamamatsu Photonics Europe GmbH
Pixcelldata Ltd.
Glencoe Software Inc.
*Profiles of these players are not included. The same will be included on request
